Highly elevated C-reactive protein levels in obese patients with COPD: A fat chance?

Clinical Nutrition

Volumn 28, Issue 6, 2009, Pages 642-647

  Breyer, Marie Kathrin ^a,b   Spruit, Martijn A ^a   Celis, Annemie P M ^c   Rutten, Erica P A ^a   Janssen, Paul P ^a   Wouters, Emiel F M ^a,d  

^a Development and Education Centre for Integrated Rehabilitation of Organ failure (CIRO) Horn   (Netherlands)

^b OTTO WAGNER HOSPITAL   (Austria)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

C reactive protein; Chronic obstructive pulmonary disease; Inflammation; Obesity

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADIPOCYTE; ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OBESITY; PULMONARY REHABILITATION; RISK ASSESSMENT;

AGED; AGING; BODY COMPOSITION; BODY MASS INDEX; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; OXYGEN INHALATION THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS;

EID: 71549115752     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2009.05.005     Document Type: Article

References (54)

1. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., and Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163 (2001 Apr) 1256-1276
2. Vestbo J., Prescott E., Almdal T., Dahl M., Nordestgaard B.G., Andersen T., et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 173 (2006 Jan 1) 79-83
3. Oga T., Nishimura K., Tsukino M., Sato S., and Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 167 (2003 Feb 15) 544-549
4. Mostert R., Goris A., Weling-Scheepers C., Wouters E.F., and Schols A.M. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med 94 (2000 Sep) 859-867
5. Pinto-Plata V.M., Cote C., Cabral H., Taylor J., and Celli B.R. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 23 (2004 Jan) 28-33
6. Schols A.M., Broekhuizen R., Weling-Scheepers C.A., and Wouters E.F. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 82 (2005 Jul) 53-59
7. Gan W.Q., Man S.F., Senthilselvan A., and Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59 (2004 Jul) 574-580
8. Spruit M.A., Gosselink R., Troosters T., Kasran A., Gayan-Ramirez G., Bogaerts P., et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 58 (2003 Sep) 752-756
9. Broekhuizen R., Wouters E.F., Creutzberg E.C., and Schols A.M. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61 (2006 Jan) 17-22
10. Watz H., Waschki B., Boehme C., Claussen M., Meyer T., and Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med 177 (2008 Apr 1) 743-751
11. Sin D.D., and Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003 Mar 25) 1514-1519
12. Mills N.L., Miller J.J., Anand A., Robinson S.D., Frazer G.A., Anderson D., et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 63 (2008 Apr) 306-311
13. Dahl M., Vestbo J., Lange P., Bojesen S.E., Tybjaerg-Hansen A., and Nordestgaard B.G. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 (2007 Feb 1) 250-255
14. Man S.F., Connett J.E., Anthonisen N.R., Wise R.A., Tashkin D.P., and Sin D.D. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 61 (2006 Oct) 849-853
15. Fabbri L.M., and Rabe K.F. From COPD to chronic systemic inflammatory syndrome?. Lancet 370 (2007 Sep 1) 797-799
16. Franciosi L.G., Page C.P., Celli B.R., Cazzola M., Walker M.J., Danhof M., et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 19 (2006) 189-199
17. Pinto-Plata V.M., Mullerova H., Toso J.F., Feudjo-Tepie M., Soriano J.B., Vessey R.S., et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 61 (2006 Jan) 23-28
18. Melbye H., Halvorsen D.S., Hartz I., Medbo A., Brox J., Eggen A.E., et al. Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromso Study 2001. Respir Med 101 (2007 Dec) 2541-2549
19. Mendall M.A., Patel P., Ballam L., Strachan D., and Northfield T.C. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 312 (1996 Apr 27) 1061-1065
20. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., and Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282 (1999 Dec 8) 2131-2135
21. Spruit M.A., Pennings H.J., Janssen P.P., Does J.D., Scroyen S., Akkermans M.A., et al. Extra-pulmonary features in COPD patients entering rehabilitation after stratification for MRC dyspnea grade. Respir Med 101 (2007 Dec) 2454-2463
22. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
23. WHO. The world health report 2002, reducing risks, promoting healthy life (2002), WHO
24. Steiner M.C., Barton R.L., Singh S.J., and Morgan M.D. Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD. Eur Respir J 19 (2002 Apr) 626-631
25. Baarends E.M., Schols A.M., Mostert R., and Wouters E.F. Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. Eur Respir J 10 (1997 Dec) 2807-2813
26. Kyle U.G., Genton L., Slosman D.O., and Pichard C. Fat-free and fat mass percentiles in 5225 healthy subjects aged 15 to 98 years. Nutrition 17 (2001 Jul-Aug) 534-541
27. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003 Jan 28) 499-511
28. Gan W.Q., Man S.F., and Sin D.D. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 127 (2005 Feb) 558-564
29. Cano N.J., Pichard C., Roth H., Court-Fortune I., Cynober L., Gerard-Boncompain M., et al. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 126 (2004 Aug) 540-546
30. Rana J.S., Mittleman M.A., Sheikh J., Hu F.B., Manson J.E., Colditz G.A., et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 27 (2004 Oct) 2478-2484
31. Blackburn Jr. W.D. Validity of acute phase proteins as markers of disease activity. J Rheumatol Suppl 42 (1994 Oct) 9-13
32. Sin D.D., Lacy P., York E., and Man S.F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004 Oct 1) 760-765
33. Palmas W., Ma S., Psaty B., Goff Jr. D.C., Darwin C., and Barr R.G. Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis. Am J Hypertens 20 (2007 Mar) 233-241
34. Albert M.A., Staggers J., Chew P., and Ridker P.M. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J 141 (2001 Jun) 893-898
35. Yudkin J.S., Stehouwer C.D., Emeis J.J., and Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19 (1999 Apr) 972-978
36. Kuller L.H., Tracy R.P., Shaten J., and Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple risk factor intervention trial. Am J Epidemiol 144 (1996 Sep 15) 537-547
37. Fantuzzi G., and Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol. 27 (2007 May) 996-1003
38. Franssen F.M., O'Donnell D.E., Goossens G.H., Blaak E.E., and Schols A.M. Obesity and the lung: 5. Obesity and COPD. Thorax 63 (2008 Dec) 1110-1117
39. Poulain M., Doucet M., Drapeau V., Fournier G., Tremblay A., Poirier P., et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron Respir Dis 5 (2008) 35-41
40. Bolton C.E., Evans M., Ionescu A.A., Edwards S.M., Morris R.H., Dunseath G., et al. Insulin resistance and inflammation - a further systemic complication of COPD. COPD 4 (2007 Jun) 121-126
41. Marquis K., Maltais F., Duguay V., Bezeau A.M., LeBlanc P., Jobin J., et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 25 (2005 Jul-Aug) 226-232 Discussion 33-34
42. Hole D.J., Watt G.C., Davey-Smith G., Hart C.L., Gillis C.R., and Hawthorne V.M. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 313 (1996 Sep 21) 711-715 Discussion 5-6
43. Landbo C., Prescott E., Lange P., Vestbo J., and Almdal T.P. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 (1999 Dec) 1856-1861
44. Calle E.E., Thun M.J., Petrelli J.M., Rodriguez C., and Heath Jr. C.W. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 341 (1999 Oct 7) 1097-1105
45. Curtis J.P., Selter J.G., Wang Y., Rathore S.S., Jovin I.S., Jadbabaie F., et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 165 (2005 Jan 10) 55-61
46. Bassuk S.S., Rifai N., and Ridker P.M. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 29 (2004 Aug) 439-493
47. Schols A.M., Buurman W.A., Staal van den Brekel A.J., Dentener M.A., and Wouters E.F. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51 (1996 Aug) 819-824
48. Eid A.A., Ionescu A.A., Nixon L.S., Lewis-Jenkins V., Matthews S.B., Griffiths T.L., et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001 Oct 15) 1414-1418
49. Bernard S., LeBlanc P., Whittom F., Carrier G., Jobin J., Belleau R., et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158 (1998 Aug) 629-634
50. Pitta F., Troosters T., Spruit M.A., Probst V.S., Decramer M., and Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171 (2005 May 1) 972-977
51. Spruit M.A., Gosselink R., Troosters T., De Paepe K., and Decramer M. Resistance versus endurance training in patients with COPD and peripheral muscle weakness. Eur Respir J 19 (2002 Jun) 1072-1078
52. Crul T., Spruit M.A., Gayan-Ramirez G., Quarck R., Gosselink R., Troosters T., et al. Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur J Clin Invest 37 (2007 Nov) 897-904
53. Barreiro E., Schols A.M., Polkey M.I., Galdiz J.B., Gosker H.R., Swallow E.B., et al. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax 63 (2008 Feb) 100-107
54. Fogarty A.W., Jones S., Britton J.R., Lewis S.A., and McKeever T.M. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 62 (2007 Jun) 515-520